News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Temperature Controlled Material Developed for Robotic Gripper Applications
When the SMP is in a soft state, it allows the gripper to make good contact with the object and conform to objects with irregular shapes or surfaces.
PCI Recognized on Technical.ly’s List of Philadelphia’s Biggest Tech Moments of 2023
In the article, Technical.ly highlights that Penn affiliated startups attracted over $1 billion in investment capital in 2023.
Penn Nobel-Prize Winners Receive Warm Welcome in Sweden
Karikó and Weissman were celebrated at several days of ceremonies and festivities in Sweden, two months after first learning the news.
Serpex Acquired by Maverix Medical
Serpex Medical leverages the power of steerable instruments to enable greater precision and access to improve the diagnosis and treatment of lung cancer.
PCI’s 8th Annual Celebration of Innovation Honors Research and Commercialization Accomplishments at Penn
On December 5th, 2023, PCI hosted its annual Celebration of Innovation, where special awards were presented for exceptional commercialization accomplishments and to celebrate Penn innovators.
Penn Engineering Researchers Invent Origami-Inspired Microbots
The goal of this innovative technology is to use the microrobots to assist in repairing peripheral nerves.
More than 260,000 Penn Medicine patients have agreed to share their DNA for research via Penn Medicine BioBank
By obtaining samples from a wide-cross section of humanity, researchers are able to cross-reference participants’ DNA with their health records and identify genetic variants for a range of diseases.
Long-term Penn Research Across Disciplines Leads to the Development of a New ‘Patch’ that Uses Natural Body Motion to Fix Disc Herniation
A new biologic “patch” that is activated by a person’s natural motion has the potential to fix herniated discs in people’s backs, according to researchers at Penn Medicine and the CMC VA Medical Cente
Carisma Therapeutics Receives FDA Clearance of Investigational New Drug Application for CT-0525, a Novel CAR-M Cell Therapy
Having received a Study May Proceed notification from the FDA, Carisma plans to initiate a Phase 1 study in the months to come and to treat the first patient in the first half of 2024.
Penn’s Leadership Role in Philadelphia’s Rapidly Growing Life Sciences Industry Highlighted
Technical.ly published an article about the future of the growth of the life sciences in Philadelphia, highlighting Penn’s role in the development of the city as a strong tech hub.